# Azidus Brasil clinical trials: 80 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 80 trials with Azidus Brasil as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Azidus Brasil: 80 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/azidus-brasil

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 80
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 80, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 10, 2025 | NCT06817096 | Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza | Azidus Brasil | Phase 3 | Not yet recruiting | Covid 19, Influenza | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06817096) |
| March 12, 2024 | NCT06303635 | Safety of UFRJvac, Trivalent COVID-19 Vaccine | Azidus Brasil | Observational | Unknown | Healthy People | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06303635) |
| November 29, 2023 | NCT06150833 | IVIG Boya: Safety, Efficacy, and Pharmacokinetics | Azidus Brasil | Phase 3 | Not yet recruiting | Primary Immunodeficiency Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06150833) |
| October 24, 2023 | NCT06097780 | Efficacy and Safety of NestaCell® in Huntington's Disease | Azidus Brasil | Phase 3 | Unknown | Huntington Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06097780) |
| October 18, 2023 | NCT06089122 | Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG | Azidus Brasil | Phase 3 | Unknown | Primary Immunodeficiency Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06089122) |
| November 2, 2022 | NCT05603403 | Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms | Azidus Brasil | Phase 4 | Completed | Signs and Symptoms, Digestive | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05603403) |
| September 15, 2022 | NCT05542693 | Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine | Azidus Brasil | Phase 2 | Unknown | COVID-19, COVID-19 Vaccine | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05542693) |
| August 17, 2021 | NCT05009277 | Study To Evaluate The Sensitivity Of The Linda Thermal Device | Azidus Brasil | Observational | Unknown | Device, Thermography, Mammography | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05009277) |
| June 22, 2020 | NCT04441398 | Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients | Azidus Brasil | Phase 2/3 | Withdrawn | covid19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04441398) |
| June 17, 2020 | NCT04435314 | Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 | Azidus Brasil | Phase 2 | Withdrawn | covid19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04435314) |
| June 9, 2020 | NCT04423861 | Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19 | Azidus Brasil | Phase 3 | Unknown | covid19 | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04423861) |
| April 20, 2020 | NCT04352465 | Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients | Azidus Brasil | Phase 1/2 | Unknown | COVID-19 | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04352465) |
| April 16, 2020 | NCT04348474 | Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19 | Azidus Brasil | Early phase 1 | Suspended | Covid-19 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04348474) |
| April 16, 2020 | NCT04348409 | Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19 | Azidus Brasil | Not applicable | Completed | COVID-19 | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04348409) |
| April 1, 2020 | NCT04329572 | Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19 | Azidus Brasil | Early phase 1 | Suspended | COVID-19 | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04329572) |
| March 20, 2020 | NCT04315987 | NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia | Azidus Brasil | Phase 2 | Completed | COVID-19 Pneumonia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04315987) |
| January 7, 2020 | NCT04219241 | Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients. | Azidus Brasil | Phase 2/3 | Unknown | Huntington Disease | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04219241) |
| June 28, 2018 | NCT03572647 | Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects. | Azidus Brasil | Phase 1 | Completed | Renal Insufficiency, Chronic | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03572647) |
| August 17, 2017 | NCT03252535 | Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease | Azidus Brasil | Phase 2 | Completed | Huntington Disease | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03252535) |
| April 5, 2016 | NCT02728115 | Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease | Azidus Brasil | Phase 1 | Unknown | Huntington Disease | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02728115) |
| September 28, 2012 | NCT01695759 | Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease. | Azidus Brasil | Phase 3 | Terminated | Chronic Kidney Disease, Anemia | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01695759) |
| September 25, 2012 | NCT01692717 | Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide | Azidus Brasil | Phase 1 | Completed | Healthy Subjects | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01692717) |
| September 25, 2012 | NCT01692171 | Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration | Azidus Brasil | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01692171) |
| September 25, 2012 | NCT01692158 | Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose | Azidus Brasil | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01692158) |
| September 14, 2012 | NCT01685359 | PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant | Azidus Brasil | Phase 1 | Completed | Healthy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01685359) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 2 |
| Phase 1 | 16 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 13 |
| Phase 3 | 38 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 31 |
| Completed | 29 |
| Suspended | 10 |
| Withdrawn | 7 |
| Not yet recruiting | 2 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 9 |
| Huntington Disease | 4 |
| Kidney Failure, Chronic | 3 |
| Psoriasis | 3 |
| Renal Insufficiency, Chronic | 3 |
| Dermatitis | 2 |
| Dermatitis, Atopic | 2 |
| Osteoarthritis | 2 |
| Anemia | 2 |
| Fatigue | 2 |
| Primary Immunodeficiency Diseases | 2 |
| Venous Thromboembolism | 2 |
| Exocrine Pancreatic Insufficiency | 1 |
| Menstruation Disturbances | 1 |
| Facies | 1 |
| Influenza, Human | 1 |
| Signs and Symptoms, Digestive | 1 |
| Folliculitis | 1 |
| Melanosis | 1 |
| Acromegaly | 1 |
| Venous Insufficiency | 1 |
| Thrombosis | 1 |
| Dwarfism, Pituitary | 1 |
| Burns | 1 |
| Inflammation | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Textile mills in the United States](https://specstream.ai/data/businesses/textile-mills/united-states)
- [Publishers in the United States](https://specstream.ai/data/businesses/publishers/united-states)
- [Naturopathic clinics in the United States](https://specstream.ai/data/businesses/naturopathic-clinics/united-states)
- [Industrial equipment manufacturers in the United States](https://specstream.ai/data/businesses/industrial-equipment-manufacturers/united-states)
- [Farming services in the United States](https://specstream.ai/data/businesses/farming-services/united-states)
- [Computer hardware companies in the United States](https://specstream.ai/data/businesses/computer-hardware-companies/united-states)
